Patent Law Weblog
recent posts
- Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (2026)
- Constellation Designs, LLC v. LG Electronics Inc. (Fed. Cir. 2026)
- Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2026)
- PTAB Reverses § 101 Rejection Where Examiner Failed to Follow the Office’s Own Guidance
- Collision Communications v. Samsung: What Good Did the Government’s Statement of Interest Do?
about
Month: December 2008
-
By Kevin E. Noonan — The Federal Circuit engaged in judicial parsimony last week, in affirming the decision below that the asserted claims of U.S. Patent No. 5,723,283 are invalid for failure to encompass statutory subject matter. The opinion, written by Judge Moore and joined by Judge Newman and District Court Judge Joseph Farnan…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring. Pfizer Inc. et al. v. Apotex Inc. et al.1:08-cv-00948; filed December 17, 2008 in the District Court of Delaware Pfizer Inc. et…
-
January 3-7, 2009 – 26th Annual National CLE Conference (Law Education Institute) – Vail, CO January 12-13, 2009 – Pharmaceutical and Biotech Patent Opinion Writing*** (American Conference Institute) – San Diego, CA January 20-21, 2009 – Bio/Pharmaceutical Summit on Legal and Regulatory Product Lifecycle Strategies*** (Center for Business Intelligence) – Baltimore, MD January 26-27, 2009…
-
By Donald Zuhn — Patent Docs periodically reports on the lobbying efforts of various players in the biotech/pharma industry (see links below for reports on first and second quarter lobbying this year). Our interest in the lobbying expenditures of these companies and organizations stems from the push by Congress over the past two years…
-
By Donald Zuhn — Earlier this week, the National Venture Capital Association (NVCA), a trade association representing the U.S. venture capital industry, released the results of its third annual survey on venture investment. Perhaps not surprisingly, the trade organization forecasts that most sectors will see a continued slowdown in venture investment in 2009. The…
-
By Donald Zuhn — Last week, the Law, Science & Technology Program at Stanford Law School announced the launch of the Stanford IP Litigation Clearinghouse (IPLC) Patent Litigation Module, a database of more than 23,000 cases filed in U.S. district courts since 2000. According to the school's release, the publicly available, online database "will…
-
By Donald Zuhn — An article in the October 10th issue of Science magazine presents the results of an analysis of litigated gene patents, and reaches the conclusion that "for the most part, fears expressed concerning human gene patents have not been manifested overtly in patent litigation." The article, entitled "Trends in Human Gene…
-
By Donald Zuhn — Last week, the Federal Circuit affirmed a finding of exceptionality and award of $16.8 million in attorneys fees by the District Court for the Southern District of New York in a case involving two Hatch-Waxman challenges to U.S. Patent No. 4,687,777. The challenges to the '777 patent had been initiated…
-
By Kevin E. Noonan — Denial of an ANDA validity challenge by generic pharmaceutical company Apotex of Sanofi-Synthelabo's Orange Book-listed patent for Plavix® was affirmed by the Federal Circuit last week. The decision, by Judge Newman, joined by Judges Lourie and Bryson, was unremarkable and should remain so, unless the Supreme Court were to…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring. Merial Ltd. v. Intervet, Inc.3:08-cv-00121; filed December 10, 2008 in the Middle District of Georgia Merial Ltd. v. Boehringer Ingelheim Vetmedica, Inc.3:08-cv-00116;…
Patent Docs 